Tumor-associated and immunochemotherapy-dependent long-term alterations of the peripheral blood NK cell compartment in DLBCL patients

References

• Robertson MJ, Ritz J. Biology and clinical relevance of human natural killer cells. Blood 1990; 76:2421-38; PMID:2265240
   PubMed Web of Science ®Google Scholar
• Knorr DA, Bachanova V, Verneris MR, Miller JS. Clinical utility of natural killer cells in cancer therapy and transplantation. Semin Immunol 2014; 26:161-72; PMID:24618042; http://dx.doi.org/10.1016/j.smim.2014.02.002
   PubMed Web of Science ®Google Scholar
• Chretien AS, Le Roy A, Vey N, Prebet T, Blaise D, Fauriat C, Olive D. Cancer-induced alterations of NK-mediated target recognition: current and investigational pharmacological strategies aiming at restoring NK-mediated anti-tumor activity. Front Immunol 2014; 5:122; PMID:24715892; http://dx.doi.org/10.3389/fimmu.2014.00122
   PubMed Web of Science ®Google Scholar
• The Non-Hodgkin's Lymphoma Classification Project. A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin's lymphoma. Blood 1997; 89:3909-18; PMID:9166827
   PubMed Web of Science ®Google Scholar
• Pasqualucci L. The genetic basis of diffuse large B-cell lymphoma. Curr Opin Hematol 2013; 20:336-44; PMID:23673341; http://dx.doi.org/10.1097/MOH.0b013e3283623d7f
   PubMed Web of Science ®Google Scholar
• Martelli M, Ferreri AJ, Agostinelli C, Di Rocco A, Pfreundschuh M, Pileri SA. Diffuse large B-cell lymphoma. Crit Rev Oncol Hematol 2013; 87:146-71; PMID:23375551; http://dx.doi.org/10.1016/j.critrevonc.2012.12.009
   PubMed Web of Science ®Google Scholar
• Molina A. A decade of rituximab: improving survival outcomes in non-Hodgkin's lymphoma. Annu Rev Med 2008; 59:237-50; PMID:18186705; http://dx.doi.org/10.1146/annurev.med.59.060906.220345
   PubMed Web of Science ®Google Scholar
• Boross P, Leusen JH. Mechanisms of action of CD20 antibodies. Am J Cancer Res 2012; 2:676-90; PMID:23226614
   PubMed Web of Science ®Google Scholar
• Glennie MJ, French RR, Cragg MS, Taylor RP. Mechanisms of killing by anti-CD20 monoclonal antibodies. Mol Immunol 2007; 44:3823-37; PMID:17768100; http://dx.doi.org/10.1016/j.molimm.2007.06.151
   PubMed Web of Science ®Google Scholar
• Weiner GJ. Rituximab: mechanism of action. Semin Hematol 2010; 47:115-23; PMID:20350658; http://dx.doi.org/10.1053/j.seminhematol.2010.01.011
   PubMed Web of Science ®Google Scholar
• Dall'Ozzo S, Tartas S, Paintaud G, Cartron G, Colombat P, Bardos P, Watier H, Thibault G. Rituximab-dependent cytotoxicity by natural killer cells: influence of FCGR3A polymorphism on the concentration-effect relationship. Cancer Res 2004; 64:4664-69; PMID:15231679; http://dx.doi.org/10.1158/0008-5472.CAN-03-2862
   PubMed Web of Science ®Google Scholar
• Bowles JA, Wang SY, Link BK, Allan B, Beuerlein G, Campbell MA, Marquis D, Ondek B, Wooldridge JE, Smith BJ, et al. Anti-CD20 monoclonal antibody with enhanced affinity for CD16 activates NK cells at lower concentrations and more effectively than rituximab. Blood 2006; 108:2648-54; PMID:16825493; http://dx.doi.org/10.1182/blood-2006-04-020057
   PubMed Web of Science ®Google Scholar
• Hatjiharissi E, Xu L, Santos DD, Hunter ZR, Ciccarelli BT, Verselis S, Modica M, Cao Y, Manning RJ, Leleu X, et al. Increased natural killer cell expression of CD16, augmented binding and ADCC activity to rituximab among individuals expressing the Fc{gamma}RIIIa-158 V/V and V/F polymorphism. Blood 2007; 110:2561-64; PMID:17475906; http://dx.doi.org/10.1182/blood-2007-01-070656
   PubMed Web of Science ®Google Scholar
• Veeramani S, Wang SY, Dahle C, Blackwell S, Jacobus L, Knutson T, Button A, Link BK, Weiner GJ. Rituximab infusion induces NK activation in lymphoma patients with the high-affinity CD16 polymorphism. Blood 2011; 118:3347-49; PMID:21768303; http://dx.doi.org/10.1182/blood-2011-05-351411
   PubMed Web of Science ®Google Scholar
• Cartron G, Dacheux L, Salles G, Solal-Celigny P, Bardos P, Colombat P, Watier H. Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgammaRIIIa gene. Blood 2002; 99:754-58; PMID:11806974; http://dx.doi.org/10.1182/blood.V99.3.754
   PubMed Web of Science ®Google Scholar
• Kim DH, Jung HD, Kim JG, Lee JJ, Yang DH, Park YH, Do YR, Shin HJ, Kim MK, Hyun MS, et al. FCGR3A gene polymorphisms may correlate with response to frontline R-CHOP therapy for diffuse large B-cell lymphoma. Blood 2006; 108:2720-25; PMID:16609067; http://dx.doi.org/10.1182/blood-2006-01-009480
   PubMed Web of Science ®Google Scholar
• de Haij S, Jansen JH, Boross P, Beurskens FJ, Bakema JE, Bos DL, Martens A, Verbeek JS, Parren PW, van de Winkel JG, et al. In vivo cytotoxicity of type I CD20 antibodies critically depends on Fc receptor ITAM signaling. Cancer Res 2010; 70:3209-17; PMID:20354182; http://dx.doi.org/10.1158/0008-5472.CAN-09-4109
   PubMed Web of Science ®Google Scholar
• Seidel UJ, Schlegel P, Lang P. Natural killer cell mediated antibody-dependent cellular cytotoxicity in tumor immunotherapy with therapeutic antibodies. Front Immunol 2013; 4:76; PMID:23543707; http://dx.doi.org/10.3389/fimmu.2013.00076
   PubMed Web of Science ®Google Scholar
• Trinchieri G. Biology of natural killer cells. Adv Immunol 1989; 47:187-376; PMID:2683611; http://dx.doi.org/10.1016/S0065-2776(08)60664-1
   PubMed Web of Science ®Google Scholar
• Huntington ND, Vosshenrich CA, Di Santo JP. Developmental pathways that generate natural-killer-cell diversity in mice and humans. Nat Rev Immunol 2007; 7:703-14; PMID:17717540; http://dx.doi.org/10.1038/nri2154
   PubMed Web of Science ®Google Scholar
• Sun JC, Lanier LL. NK cell development, homeostasis and function: parallels with CD8⁺ T cells. Nat Rev Immunol 2011; 11:645-57; PMID:21869816; http://dx.doi.org/10.1038/nri3044
   PubMed Web of Science ®Google Scholar
• Yu J, Freud AG, Caligiuri MA. Location and cellular stages of natural killer cell development. Trends Immunol 2013; 34:573-82; PMID:24055329; http://dx.doi.org/10.1016/j.it.2013.07.005
   PubMed Web of Science ®Google Scholar
• Bottino C, Moretta L, Moretta A. NK cell activating receptors and tumor recognition in humans. Curr Top Microbiol Immunol 2006; 298:175-82; PMID:16323416
   PubMed Web of Science ®Google Scholar
• Lanier LL. Up on the tightrope: natural killer cell activation and inhibition. Nat Immunol 2008; 9:495-502; PMID:18425106; http://dx.doi.org/10.1038/ni1581
   PubMed Web of Science ®Google Scholar
• Long EO, Sik Kim H, Liu D, Peterson ME, Rajagopalan S. Controlling natural killer cell responses: integration of signals for activation and inhibition. Annu Rev Immunol 2013; 31:227-58; PMID:23516982; http://dx.doi.org/10.1146/annurev-immunol-020711-075005
   PubMed Web of Science ®Google Scholar
• Kruse PH, Matta J, Ugolini S, Vivier E. Natural cytotoxicity receptors and their ligands. Immunol Cell Biol 2014; 92:221-9; PMID:24366519; http://dx.doi.org/10.1038/icb.2013.98
   PubMed Web of Science ®Google Scholar
• Trinchieri G, Valiante N. Receptors for the Fc fragment of IgG on natural killer cells. Nat Immun 1993; 12:218-34.
   PubMedGoogle Scholar
• Perussia B. Fc receptors on natural killer cells. Curr Top Microbiol Immunol 1998; 230:63-88; PMID:9586351
   PubMed Web of Science ®Google Scholar
• Nausch N, Cerwenka A. NKG2D ligands in tumor immunity. Oncogene 2008; 27:5944-58; PMID:18836475; http://dx.doi.org/10.1038/onc.2008.272
   PubMed Web of Science ®Google Scholar
• Burgess SJ, Maasho K, Masilamani M, Narayanan S, Borrego F, Coligan JE. The NKG2D receptor: immunobiology and clinical implications. Immunol Res 2008; 40:18-34; PMID:18193361; http://dx.doi.org/10.1007/s12026-007-0060-9
   PubMed Web of Science ®Google Scholar
• El-Gazzar A, Groh V, Spies T. Immunobiology and conflicting roles of the human NKG2D lymphocyte receptor and its ligands in cancer. J Immunol 2013; 191:1509-15; PMID:23913973; http://dx.doi.org/10.4049/jimmunol.1301071
   PubMed Web of Science ®Google Scholar
• Le Bert N, Gasser S. Advances in NKG2D ligand recognition and responses by NK cells. Immunol Cell Biol 2014; 92:230-6; PMID:24445601; http://dx.doi.org/10.1038/icb.2013.111
   PubMed Web of Science ®Google Scholar
• Raulet DH, Gasser S, Gowen BG, Deng W, Jung H. Regulation of ligands for the NKG2D activating receptor. Annu Rev Immunol 2013; 31:413-41; PMID:23298206; http://dx.doi.org/10.1146/annurev-immunol-032712-095951
   PubMed Web of Science ®Google Scholar
• Wiemann K, Mittrücker HW, Feger U, Welte SA, Yokoyama WM, Spies T, Rammensee HG, Steinle A. Systemic NKG2D down-regulation impairs NK and CD8 T cell responses in vivo. J Immunol 2005; 175:720-9; PMID:16002667; http://dx.doi.org/10.4049/jimmunol.175.2.720
   PubMed Web of Science ®Google Scholar
• Guerra N, Tan YX, Joncker NT, Choy A, Gallardo F, Xiong N, Knoblaugh S, Cado D, Greenberg NM, Raulet DH. NKG2D-deficient mice are defective in tumor surveillance in models of spontaneous malignancy. Immunity 2008; 28:571-80; PMID:18394936; http://dx.doi.org/10.1016/j.immuni.2008.02.016
   PubMed Web of Science ®Google Scholar
• Grzywacz B, Kataria N, Verneris MR. CD56(dim)CD16(+) NK cells downregulate CD16 following target cell induced activation of matrix metalloproteinases. Leukemia 2007; 21:356-9; PMID:17251901; http://dx.doi.org/10.1038/sj.leu.2404499
   PubMed Web of Science ®Google Scholar
• Romee R, Foley B, Lenvik T, Wang Y, Zhang B, Ankarlo D, Luo X, Cooley S, Verneris M, Walcheck B, et al. NK cell CD16 surface expression and function is regulated by a disintegrin and metalloprotease-17 (ADAM17). Blood 2013; 121:3599-608; PMID:23487023; http://dx.doi.org/10.1182/blood-2012-04-425397
   PubMed Web of Science ®Google Scholar
• Dunn GP, Koebel CM, Schreiber RD. Interferons, immunity and cancer immunoediting. Nat Rev Immunol 2006; 6:836-48; PMID:17063185; http://dx.doi.org/10.1038/nri1961
   PubMed Web of Science ®Google Scholar
• Cox MC, Nofroni I, Ruco L, Amodeo R, Ferrari A, La Verde G, Cardelli P, Montefusco E, Conte E, Monarca B, et al. Low absolute lymphocyte count is a poor prognostic factor in diffuse-large-B-cell-lymphoma. Leuk Lymphoma 2008; 49; 1745-51; PMID:18798109; http://dx.doi.org/10.1080/10428190802226425
   PubMed Web of Science ®Google Scholar
• Watanabe R, Tomita N, Itabashi M, Ishibashi D, Yamamoto E, Koyama S, Miyashita K, Takahashi H, Nakajima Y, Hattori Y, et al. Peripheral blood absolute lymphocyte/monocyte ratio as a useful prognostic factor in diffuse large B-cell lymphoma in the rituximab era. Eur J Haematol 2014; 92:204-10; PMID:24283206; http://dx.doi.org/10.1111/ejh.12221
   PubMed Web of Science ®Google Scholar
• Porrata LF, Ristow KM, Habermann TM, Witzig TE, Colgan JP, Inwards DJ, Ansell SM, Micallef IN, Johnston PB, Nowakowski G, et al. Peripheral blood absolute lymphocyte/monocyte ratio during rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone treatment cycles predicts clinical outcomes in diffuse large B-cell lymphoma. Leuk Lymphoma 2014; 55:2728-2738; PMID:24547705; http://dx.doi.org/10.1038/sj.bmt.1705565
   PubMed Web of Science ®Google Scholar
• Plonquet A, Haioun C, Jais JP, Debard AL, Salles G, Bene MC, Feugier P, Rabian C, Casasnovas O, Labalette M, et al. Peripheral blood natural killer cell count is associated with clinical outcome in patients with aaIPI 2–3 diffuse large B-cell lymphoma. Ann Oncol 2007; 18:1209-15; PMID:17496307; http://dx.doi.org/10.1093/annonc/mdm110
   PubMed Web of Science ®Google Scholar
• Danielou-Lazareth A, Henry G, Geromin D, Khaznadar Z, Briere J, Tamouza R, Cayuela JM, Thieblemont C, Toubert A, Dulphy N. At diagnosis, diffuse large B-cell lymphoma patients show impaired rituximab-mediated NK-cell cytotoxicity. Eur J Immunol 2013; 43:1383-88; PMID:23400905; http://dx.doi.org/10.1002/eji.201242733
   PubMed Web of Science ®Google Scholar
• Fischer L, Penack O, Gentilini C, Nogai A, Muessig A, Thiel E, Uharek L. The anti-lymphoma effect of antibody-mediated immunotherapy is based on an increased degranulation of peripheral blood natural killer (NK) cells. Exp Hematol 2006; 34:753-9; PMID:16728280; http://dx.doi.org/10.1016/j.exphem.2006.02.015
   PubMed Web of Science ®Google Scholar
• Inagaki A, Ishida T, Yano H, Ishii T, Kusumoto S, Ito A, Ri M, Mori F, Ding J, Komatsu H, et al. Expression of the ULBP ligands for NKG2D by B-NHL cells plays an important role in determining their susceptibility to rituximab-induced ADCC. Int J Cancer 2009; 125:212-21; PMID:19358282; http://dx.doi.org/10.1002/ijc.24351
   PubMed Web of Science ®Google Scholar
• Deguine J, Breart B, Lemaître F, Bousso P. Cutting Edge: Tumor-Targeting Antibodies Enhance NKG2D-Mediated NK Cell Cytotoxicity by Stabilizing NK Cell–Tumor Cell Interactions. J Immunol 2012; 189:5493-97; PMID:23183896; http://dx.doi.org/10.4049/jimmunol.1202065
   PubMed Web of Science ®Google Scholar
• Kuriyama Y, Nakano M, Kawanishi Y, Iwase O, Aizawa S, Toyama K. Cytotoxic lymphocytes in the peripheral blood of patients with B cell lymphomas. Leukemia 1995; 9:2123-6; PMID:8609727
   PubMed Web of Science ®Google Scholar
• Tursz T, Dokhelar MC, Lipinski M, Amiel JL. Low natural killer cell activity in patients with malignant lymphoma. Cancer 1982; 50:2333-5; PMID:6958348; http://dx.doi.org/10.1002/1097-0142(19821201)50:11%3c2333::AID-CNCR2820501119%3e3.0.CO;2-W
   PubMed Web of Science ®Google Scholar
• Ono K. Clinical significance of natural killing activity in patients with advanced lymphoma. J Clin Immunol 1998; 18:132-41; PMID:9533657; http://dx.doi.org/10.1023/A:1023298917191
   PubMed Web of Science ®Google Scholar
• Kim JK, Chung JS, Shin HJ, Song MK, Yi JW, Shin DH, Lee DS, Baek SM. Influence of NK cell count on the survival of patients with diffuse large B-cell lymphoma treated with R-CHOP. Blood Res 2014; 49:162-9; PMID:25325035; http://dx.doi.org/10.5045/br.2014.49.3.162
   PubMedGoogle Scholar
• Markasz L, Stuber G, Vanherberghen B, Flaberg E, Olah E, Carbone E, Eksborg S, Klein E, Skribek H, Szekely L. Effect of frequently used chemotherapeutic drugs on the cytotoxic activity of human natural killer cells. Mol Cancer Ther 2007; 6:644-54; PMID:17308061; http://dx.doi.org/10.1158/1535-7163.MCT-06-0358
   PubMed Web of Science ®Google Scholar
• Katz P, Zaytoun AM, Lee JH Jr. Mechanisms of human cell-mediated cytotoxicity. III. dependence of natural killing on microtubule and microfilament integrity. J Immunol 1982; 129:2816-25; PMID:6890568
   PubMed Web of Science ®Google Scholar
• Riccardi C, Barlozzari T, Santoni A, Herberman RB, Cesarini C. Transfer to cyclophosphamide-treated mice of natural killer (NK) cells and in vivo natural reactivity against tumors. J Immunol 1981; 126:1284-89; PMID:7204966
   PubMed Web of Science ®Google Scholar
• Cartron G, Blasco H, Paintaud G, Watier H, Le Guellec C. Pharmacokinetics of rituximab and its clinical use: thought for the best use? Crit Rev Oncol Hematol 2007; 62:43-52; PMID:17287129; http://dx.doi.org/10.1016/j.critrevonc.2006.09.004
   PubMed Web of Science ®Google Scholar
• Arpon DR, Gandhi MK, Martin JH. A new frontier in haematology - combining pharmacokinetic with pharmacodynamic factors to improve choice and dose of drug. Br J Clin Pharmacol 2014; 78:274-81; PMID:24433338; http://dx.doi.org/10.1111/bcp.12318
   PubMed Web of Science ®Google Scholar
• Pende D, Rivera P, Marcenaro S, Chang CC, Biassoni R, Conte R, Kubin M, Cosman D, Ferrone S, Moretta L. Major histocompatibility complex class I-related chain A and UL16-binding protein expression on tumor cell lines of different histotypes: analysis of tumor susceptibility to NKG2D-dependent natural killer cell cytotoxicity. Cancer Res 2002; 62:6178-86; PMID:12414645
   PubMed Web of Science ®Google Scholar
• G Mentlik, James A, Cohen AD, Campbell KS. Combination immune therapies to enhance anti-tumor responses by NK cells. Front Immunol 2013; 4:1-12; PMID:23355837
   PubMed Web of Science ®Google Scholar
• Kellner C, Hallack D, Glorius P, Staudinger M, Mohseni Nodehi S, de Weers M, van de Winkel JG, Parren PW, Stauch M, et al. Fusion proteins between ligands for NKG2D and CD20-directed single-chain variable fragments sensitize lymphoma cells for natural killer cell-mediated lysis and enhance antibody-dependent cellular cytotoxicity. Leukemia 2012; 26:830-4; PMID:22005785; http://dx.doi.org/10.1038/leu.2011.288
   PubMed Web of Science ®Google Scholar
• Zhang Y, Wallace DL, de Lara CM, Ghattas H, Asquith B, Worth A, Griffin GE, Taylor GP, Tough DF, Beverley PC, et al. In vivo kinetics of human natural killer cells: the effects of ageing and acute and chronic viral infection. Immunology 2007; 121:258-65; PMID:17346281; http://dx.doi.org/10.1111/j.1365-2567.2007.02573.x
   PubMed Web of Science ®Google Scholar
• Charbonneau B, Maurer MJ, Ansell SM, Slager SL, Fredericksen ZS, Ziesmer SC, Macon WR, Habermann TM, Witzig TE, Link BK, et al. Pretreatment circulating serum cytokines associated with follicular and diffuse large B-cell lymphoma: a clinic-based case-control study. Cytokine 2012; 60:882-9; PMID:23010502; http://dx.doi.org/10.1016/j.cyto.2012.08.028
   PubMed Web of Science ®Google Scholar
• McAllister SS, Weinberg RA. The tumour-induced systemic environment as a critical regulator of cancer progression and metastasis. Nat Cell Biol 2014; 16:717-27; PMID:25082194; http://dx.doi.org/10.1038/ncb3015
   PubMed Web of Science ®Google Scholar
• Murawski N, Pfreundschuh M, Zeynalova S, Poeschel V, Hänel M, Held G, Schmitz N, Viardot A, Schmidt C, Hallek M, et al. Optimization of rituximab for the treatment of DLBCL (I): dose-dense rituximab in the DENSE-R-CHOP-14 trial of the DSHNHL. Ann Oncol 2014; 25:1800-06; PMID:24928834; http://dx.doi.org/10.1093/annonc/mdu208
   PubMed Web of Science ®Google Scholar
• Lindorfer MA, Wiestner A, Zent CS, Taylor RP. Monoclonal antibody (mAb)-based cancer therapy: Is it time to reevaluate dosing strategies?. Oncoimmunology 2012; 1:959-61; PMID:23162771; http://dx.doi.org/10.4161/onci.20368
   PubMed Web of Science ®Google Scholar
• Gluck WL, Hurst D, Yuen A, Levine AM, Dayton MA, Gockerman JP, Lucas J, Denis-Mize K, Tong B, Navis D, et al. Phase I studies of interleukin (IL)-2 and rituximab in B-cell non-hodgkin's lymphoma: IL-2 mediated natural killer cell expansion correlations with clinical response. Clin Cancer Res 2004; 10:2253-64; PMID:15073100; http://dx.doi.org/10.1158/1078-0432.CCR-1087-3
   PubMed Web of Science ®Google Scholar
• Eisenbeis CF, Grainger A, Fischer B, Baiocchi RA, Carrodeguas L, Roychowdhury S, Chen L, Banks AL, Davis T, Young D, et al. Combination immunotherapy of B-cell non-Hodgkin's lymphoma with rituximab and interleukin-2: a preclinical and phase I study. Clin Cancer Res 2004; 10:6101-10; PMID:15447996; http://dx.doi.org/10.1158/1078-0432.CCR-04-0525
   PubMed Web of Science ®Google Scholar
• Ysebaert L, Gross E, Kühlein E, Blanc A, Corre J, Fournié JJ, Laurent G, Quillet-Mary A. Immune recovery after fludarabine-cyclophosphamide-rituximab treatment in B-chronic lymphocytic leukemia: implication for maintenance immunotherapy. Leukemia 2010; 24:1310-16; PMID:20463751; http://dx.doi.org/10.1038/leu.2010.89
   PubMed Web of Science ®Google Scholar
• Kohrt HE, Thielens A, Marabelle A, Sagiv-Barfi I, Sola C, Chanuc F, Fuseri N, Bonnafous C, Czerwinski D, Rajapaksa A, et al. Anti-KIR antibody enhancement of anti-lymphoma activity of natural killer cells as monotherapy and in combination with anti-CD20 antibodies. Blood 2014; 123:678-86; PMID:24326534; http://dx.doi.org/10.1182/blood-2013-08-519199
   PubMed Web of Science ®Google Scholar
• Du J, Lopez-Verges S, Pitcher BN, Johnson J, Jung SH, Zhou L, Hsu K, Czuczman MS, Cheson B, Kaplan L, et al. CALGB 150905 (Alliance): rituximab broadens the antilymphoma response by activating unlicensed NK cells. Cancer Immunol Res 2014; 2:878-89; PMID:24958280; http://dx.doi.org/10.1158/2326-6066.CIR-13-0158
   PubMed Web of Science ®Google Scholar
• Klimo P, Connors JM. MACOP-B chemotherapy for the treatment of diffuse large-cell lymphoma. Ann Intern Med 1985; 102:596-602; PMID:2580468; http://dx.doi.org/10.7326/0003-4819-102-5-596
   PubMed Web of Science ®Google Scholar
• Cheson BD, Pfistner B, Juweid ME, Gascoyne RD, Specht L, Horning SJ, Coiffier B, Fisher RI, Hagenbeek A, Zucca E, et al. Revised response criteria for malignant lymphoma. J Clin Oncol 2007; 25:579-86; PMID:17242396; http://dx.doi.org/10.1200/JCO.2006.09.2403
   PubMed Web of Science ®Google Scholar
• Palmieri G, Serra A, De Maria R, Gismondi A, Milella M, Piccoli M, Frati L, Santoni A. Cross-linking of alpha 4 beta 1 and alpha 5 beta 1 fibronectin receptors enhances natural killer cell cytotoxic activity. J Immunol 1995; 155:5314-22; PMID:7594545
   PubMed Web of Science ®Google Scholar
• Cerboni C, Ardolino M, Santoni A, Zingoni A. Detuning CD8+ T lymphocytes by down-regulation of the activating receptor NKG2D: role of NKG2D ligands released by activated T cells. Blood 2009; 113:2955-64; PMID:19124832; http://dx.doi.org/10.1182/blood-2008-06-165944
   PubMed Web of Science ®Google Scholar
• Waldhauer I, Steinle A. Proteolytic release of soluble UL16-binding protein 2 from tumor cells. Cancer Res 2006; 66:2520-6; PMID:16510567; http://dx.doi.org/10.1158/0008-5472.CAN-05-2520
   PubMed Web of Science ®Google Scholar